Back to today’s briefing

Story perspectives

New Weight-Loss Drug Mounjaro Sparks $150 Billion Market

8/6/2025

50 3

Summary

Mounjaro Revolutionizes Weight-Loss

In Canada, where 27.4% of adults struggle with obesity, the newly approved weight-loss drug Mounjaro is generating excitement due to its impressive results in clinical trials. Korean companies are also stepping up, creating alternatives like Efpeglenatide, focusing on affordability and better tolerance. The global market for obesity medications is projected to soar to $150 billion by 2035.

Summary

NICE Advocates Weight Management

Obesity impacts one in four adults in the UK, with 1.5 million turning to weight loss injections like Wegovy and Mounjaro. NICE emphasizes the need for structured support for at least a year after treatment to maintain progress. Yet, delays in NHS implementation and restricted access for private users threaten the success of long-term weight management efforts.

1 of 2

Mounjaro Revolutionizes Weight-Loss

In Canada, where 27.4% of adults struggle with obesity, the newly approved weight-loss drug Mounjaro is generating excitement due to its impressive results in clinical trials. Korean companies are also stepping up, creating alternatives like Efpeglenatide, focusing on affordability and better tolerance. The global market for obesity medications is projected to soar to $150 billion by 2035.

1 / 2